Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
- 29 August 2007
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 82 (4), 381-388
- https://doi.org/10.1038/sj.clpt.6100317
Abstract
The molecular target of rapamycin (mTOR) is central to a complex intracellular signaling pathway and is involved in diverse processes including cell growth and proliferation, angiogenesis, autophagy, and metabolism. Although sirolimus (rapamycin), the oldest inhibitor of mTOR, was discovered more than 30 years ago, renewed interest in this pathway is evident by the numerous rapalogs recently developed. These newer agents borrow from the structure of sirolimus and, although there are some pharmacokinetic differences, they appear to differ little in terms of pharmacodynamic effects and overall tolerability. Given the multitude of potential applications for this class of agents and the decrease in cost that can be expected upon the expiration of sirolimus patents, renewed focus on this agent is warranted.Keywords
This publication has 102 references indexed in Scilit:
- Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood, 2006
- Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)Blood, 2006
- Predicted mechanisms of resistance to mTOR inhibitorsBritish Journal of Cancer, 2006
- Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferationBritish Journal of Pharmacology, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal Of Cancer, 2006
- The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 2005
- Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositisJournal of the American Academy of Dermatology, 2005
- Mechanism of action of the immunosuppressant rapamycinLife Sciences, 1995
- Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD miceClinical and Experimental Immunology, 1992